Buparlisib helps overcome endocrine resistance in metastatic breast cancer: BELLE-2 trial results
Автор: ecancer
Загружено: 2016-01-06
Просмотров: 381
Описание:
Dr Campone talks to ecancertv at SABCS 2015 about the first results from the randomised, phase III BELLE-2 trial that assessed the the efficacy and safety of combining the PI3K inhibitor buparlisib with the endocrine therapy fulvestrant in postmenopausal women with endocrine resistant, hormone receptor (HR)-positive, HER2-negative metastatic breast cancer.
Activation of the PI3K pathway is a hallmark of resistance to endocrine therapy, Dr Campone explains. Early data suggest that using a PI3K inhibitor may be able to help reverse endocrine resistance and so the BELLE-2 trial was designed to look at this question further.
More than 1,140 women who were refractory to aromatase inhibitor therapy were enrolled into the study and stratified based on their PI3K pathway status measured in archival tumor tissue.
A 22% reduction in PFS was seen comparing buparlisib plus fulvestrant versus fulvestrant plus placebo in the full population, with respective median PFS of 6.9 and 5 months.
Pre-specified analyses showed that characterizing PIK3CA mutation in circulating tumour DNA at trial entry could identify patients that may benefit from the buparlisib/fulvestrant combination.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
